About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Attacking Hepatocellular Carcinoma With Personalised T Cell Therapy

by Anjali Aryamvally on April 14, 2018 at 1:36 PM
Font : A-A+

Attacking Hepatocellular Carcinoma With Personalised T Cell Therapy

Personalized T cell therapy has resulted in an objective positive response in a patient with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC). The T cells were engineered to carry HBV-specific T cell receptors (TCRs) and showed clinical effectiveness in a patient with hepatitis B surface antigen (HBsAg)-negative HCC metastases in the lungs following liver transplant. The patient, described in a presentation at The International Liver Congress 2018 in Paris, France, had a volumetric reduction of almost all lung lesions and no new lesions detected in the lung or liver.

Advertisement


Hepatocellular carcinoma (HCC) is the most common primary liver cancer and more than 50% of cases around the world are thought to be associated with chronic HBV. With a poor prognosis and limited therapeutic options, HCC is the second most common cause of cancer mortality worldwide. Liver transplantation is an option for some patients but HCC recurs in up to 20% of cases, with the lungs the most common site of metastases. Cytotoxic T cells play a key role in killing cancerous and infected cells when TCRs on their surface recognize short epitopes presented on the affected cell's surface and initiate a series of cytotoxic mechanisms. In HBV-related HCC tumours, integrated HBV DNA can result in both oncogenic transformation and expression of HBV epitopes on the cell surface.

'We hypothesized that HBV transcriptomic profiles of HCC cells could guide the selection of HBV-specific TCRs to be used in engineering T cells for HCC-targeted immunotherapy.' explained Dr Anthony Tan from the Emerging Infectious Diseases Programme at Duke-NUS Medical School in Singapore, the lead author of the study. 'We first had to test if short, integrated HBV DNA fragments in tumour cells can produce HBV epitopes recognized by cytotoxic T cells'.
Advertisement

Characterization of the expression of short, specific regions of integrated HBV DNA in natural HBV-related HCC lines negative for serological markers of HBV infection identified HBV epitopes that were functionally presented on the cell surface. These HCC cells could be lysed in vitro by T cells engineered to express TCRs specific for the epitopes that had been identified. A similar analysis was able to identify a region of HBV envelope encoded by integrated HBV DNA fragments derived from the primary HCC of a liver transplant patient with HBsAg-negative HCC metastases in the lungs. The TCR specific for this HBV envelope region was introduced into T cells using mRNA electroporation. Multiple adoptive transfers of the resulting HBV-specific TCR T cells into the patient were performed over a period of 6 months.

No therapy-related adverse events were observed, and computed tomography imaging performed before and during therapy showed an objective positive response with a volumetric reduction of nearly all lung lesions detected, with no new lesions detected in the lung or liver to date. As of January 2018, the tumour lesions in the lung remain stable.

'The use of mRNA electroporation for exogenous TCR expression reduces the potential toxicity of this approach compared with previous techniques using viral vectors,' said Dr Tan. 'Further development of this new immunotherapeutic strategy may offer new hope of a cure for HCC'.

'This study further explores the potentially beneficial role of immunotherapy in the management of advanced HCC', said Prof. Alejandro Forner from the Hospital Clinic Barcelona, Spain, and EASL Governing Board Member. 'With this interesting approach, the authors have been able to develop a personalized T cell adoptive immunotherapy for patients with HBV-related HCC with promising signs of clinical effectiveness. Further studies will be needed to confirm that this strategy is a viable option for patients'.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First-Ever Successful Pig-To-Human Kidney Transplantation
World Osteoporosis Day 2021 -
Spirituality and Mental Health
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Parkinsons Disease Surgical Treatment Reiki and Pranic Healing Liver Breast Cancer Radiofrequency Ablation for Liver Cancer Tumors Hepatectomy Hepatomegaly 

Recommended Reading
Study Sheds Light on Fibrolamellar Hepatocellular Carcinoma, a Rare Childhood Cancer
Advanced-stage fibrolamellar hepatocellular carcinoma, a rare childhood liver cancer can spread to ....
Chimeric Gene the Driving Factor for Hepatocellular Carcinoma
Study identifies the fusion of two genes called the chimeric to be driving genetic factor for ......
Pathogenesis of Hepatitis B Virus-Associated Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the few cancers in which a continued increase in incidence has .....
NSAID Use Linked to Reduced Hepatocellular Carcinoma Risk and Mortality Due to Chronic Liver Disease: Study
According to a study, researchers have found that aspirin use is associated with a decreased risk .....
Breast Cancer
Breast cancer is a cancer that affects the breasts or mammary glands. Early detection and lifestyle ...
Hepatomegaly
Hepatomegaly or an enlarged liver can be a symptom or a complication of many different diseases whic...
Radiofrequency Ablation for Liver Cancer Tumors
All you need to know on Radiofrequency Ablation (RFA) therapy for liver cancer including treatment, ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use